The average one-year price target for Adaptive Biotechnologies (NasdaqGS:ADPT) has been revised to $16.76 / share. This is an increase of 17.35% from the prior estimate of $14.28 dated September 27, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $11.11 to a high of $21.00 / share. The average price target represents a decrease of 0.96% from the latest reported closing price of $16.92 / share.
What is the Fund Sentiment?
There are 491 funds or institutions reporting positions in Adaptive Biotechnologies. This is an increase of 49 owner(s) or 11.09% in the last quarter. Average portfolio weight of all funds dedicated to ADPT is 0.21%, an increase of 29.64%. Total shares owned by institutions decreased in the last three months by 1.92% to 178,047K shares. 
The put/call ratio of ADPT is 0.30, indicating a bullish outlook.
What are Other Shareholders Doing?
Viking Global Investors holds 29,994K shares representing 19.70% ownership of the company. No change in the last quarter.
Rubric Capital Management holds 6,257K shares representing 4.11% ownership of the company. In its prior filing, the firm reported owning 13,118K shares , representing a decrease of 109.66%. The firm decreased its portfolio allocation in ADPT by 36.96% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 4,489K shares representing 2.95% ownership of the company. In its prior filing, the firm reported owning 4,488K shares , representing an increase of 0.01%. The firm increased its portfolio allocation in ADPT by 39.91% over the last quarter.
Nikko Asset Management Americas holds 4,300K shares representing 2.82% ownership of the company. In its prior filing, the firm reported owning 6,086K shares , representing a decrease of 41.54%. The firm decreased its portfolio allocation in ADPT by 14.24% over the last quarter.
ARK Investment Management holds 4,016K shares representing 2.64% ownership of the company. In its prior filing, the firm reported owning 7,733K shares , representing a decrease of 92.52%. The firm decreased its portfolio allocation in ADPT by 40.34% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
